Apr. 9, 2015, 12:41 PM
- Rosetta Genomics (ROSG +0.7%) acquires CynoGen (d/b/a PersonalizeDx) from Prelude, a portfolio company of venture capital firm Fjord Ventures, for $2M in cash and 500K shares of ROSG stock.
- Lake Forest, CA-based PersonalizeDx provides cancer-related molecular diagnostics services to clinicians, pathologists and other reference laboratories in the U.S.
- The transaction will enable Rosetta to obtain the rights to Prelude's novel assay for ductal carcinoma in situ, the earliest form of breast cancer characterized by the presence of abnormal cells inside a milk duct in the breast.
Rosetta Genomics Ltd. develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers... More
Industry: Diagnostic Substances
Country: United States
Other News & PR